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Summary
Background:  The  role  of  thrombus
intervention  (PPCI)  remains  a  ma
Methods  and  results:  A  total  of  21
Myocardial  Infarction  Registry,  a  
was compared  with  1360  (64.6%)  
outcomes at  12-months  of  overa
were assessed  using  Cox  regressio
signiﬁcant difference  among  over
tein (GP)  IIb/IIIa  inhibitor  during  P
(CI) 0.126—0.860,  p  =  0.023]  and  
0.516, 95%  CI  0.275—0.971,  p  =  0.0
major adverse  cardiac  events  (MA
Conclusions:  Although  TA  does  no
PPCI, TA  for  LAD  occlusion  impro
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rimary  percutaneous  coronary  intervention  (PCI)  in
atients  with  acute  ST-segment  elevation  myocardial  infarc-
ion  (STEMI)  is  the  gold  standard  strategy  [1].  Stent
mplantation  has  been  shown  to  increase  reperfusion  rate,
nd  improve  mid-  and  long-term  outcomes  [2].  Regard-
ng  thrombus  aspiration  (TA)  during  primary  PCI,  TAPAS
thrombus  aspiration  during  percutaneous  coronary  inter-
ention  in  acute  myocardial  infarction  study)  [3,4], EXPIRA
thrombectomy  with  export  catheter  in  infarct-related
rtery  during  primary  percutaneous  coronary  intervention)
5]  and  two  different  meta-analyses  [6,7]  demonstrated  that
A  improved  clinical  outcomes  as  well  as  reperfusion  status.
merican  College  of  Cardiology/American  Heart  Association
ACC/AHA)  guidelines  for  the  management  of  patients  with
TEMI  recommend  TA  as  Class  II  a,  Level  of  Evidence  B
8].
However,  some  meta-analyses  [9—11]  and  randomized
ontrolled  trials  (RCTs)  [12—15]  have  shown  that  TA  did  not
mprove  clinical  outcomes  but  improved  only  reperfusion
urrogate  endpoints.  Consequently,  the  effectiveness  of  TA
emains  a  matter  of  controversy.  Even  if  TA  is  effective  in
TEMI  patients,  it  is  unclear  which  clinical  settings  are  more
ffective  in  those  who  underwent  TA.
We  therefore  investigated  not  only  clinical  impacts  of  TA,
ut  also  which  settings  were  effective  for  reducing  clinical
vents  as  subgroup  analyses.
ethods
orea  Acute  Myocardial  Infarction  Registry
he  Korea  Acute  Myocardial  Infarction  Registry  (KAMIR)  is
 Korean  prospective  multicenter  online  registry  designed
o  describe  characteristics  and  clinical  outcomes  of  Korean
atients  with  acute  MI  and  reﬂect  current  practice  of  man-
gement  in  Korea.  The  registry  included  52  community  and
niversity  hospitals  for  primary  PCI.  Data  were  collected  at
ach  site  by  a  well-trained  study  coordinator  based  on  a
tandardized  protocol.  The  study  protocol  was  approved  by
he  ethics  committee  at  each  participating  institution  and
n
d
s
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 aspiration  (TA)  as  an  adjunct  to  primary  percutaneous  coronary
tter  of  controversy.
05  patients  enrolled  in  the  nationwide  prospective  Korea  Acute
cohort  of  745  (35.4%)  patients  who  underwent  TA  during  PPCI
patients  who  underwent  conventional  PCI  without  TA.  Clinical
ll  enrolled  patients  and  subgroups  according  to  key  variables
n  models  adjusted  by  propensity  score.  Although  there  was  no
all  patients,  in  subgroup  analyses,  administration  of  glycopro-
PCI  [adjusted  hazard  ratio  (HR)  0.329,  95%  conﬁdence  interval
left  anterior  descending  (LAD)  as  a  culprit  lesion  (adjusted  HR
40)  were  the  settings,  in  which  TA  was  associated  with  a  lower
CE)  rate  compared  with  non-TA.
t  improve  clinical  outcomes  in  overall  patients  who  underwent
ves  12-month  MACE.  Furthermore,  use  of  GP  IIb/IIIa  inhibitor
n  clinical  outcomes.
ology.  Published  by  Elsevier  Ltd.  All  rights  reserved.
ll  patients  were  informed  about  their  participation  in  this
egistry  and  written  informed  consent  was  taken.
tudy  population
 total  of  2105  patients  who  underwent  primary  PCI  were
nrolled  in  the  present  study  from  December  2007  to
ctober  2009,  and  745  (35.4%)  patients  received  manual
A  during  primary  PCI  and  1360  (64.6%)  did  not.  As  sub-
roup  analyses,  age  <65  years  (n  =  1150),  age    65  years
n  =  952),  male  (n  =  1583),  female  (n  =  521),  door  to  bal-
oon  time  <  90  min  (n  =  820),  door  to  balloon  time    90  min
n  =  1159),  symptom  to  balloon  time  <  4  h (n  =  1294),  symp-
om  to  balloon  time    4  h (n  =  709),  history  of  diabetes
ellitus  (n  =  501),  non-diabetes  mellitus  (n  =  1561),  history
f  hyperlipidemia  (n  =  248),  non-hyperlipidemia  (n  =  1721),
se  of  glycoprotein  (GP)  II  b/III  a  inhibitor  during  PCI
n  =  639),  non-use  of  GP  II  b/III  a  inhibitor  during  PCI
n  =  1450),  culprit  lesion  in  left  anterior  descending  (LAD)
n  =  1073),  left  circumﬂex  (LCX)  (n  =  230),  right  coronary
rtery  (RCA)  (n  =  755),  Type  A/B1  lesion  (n  =  452),  Type  B2/C
esion  (n  =  1415),  preprocedural  Thrombolysis  In  Myocardial
nfarction  (TIMI)  ﬂow  grade  0  (n  =  1142),  preprocedural  TIMI
ow  grade  1—3  (n  =  834),  left  ventricular  ejection  fraction
LVEF)  <35%  (n  =  133),  LVEF    35%  (n  =  1798)  were  evaluated.
eﬁnitions  and  clinical  endpoints
n  this  registry,  manual  thrombus  aspiration  devices  such
s  Thrombuster® (Kaneka,  Japan)  were  used  and  decision
f  whether  to  use  depended  on  operators.  Acute  MI  was
eﬁned  by  clinical  signs  or  symptoms,  increased  cardiac
iomarkers  (creatine  kinase-MB,  troponin-I,  or  troponin-
),  and  12-lead  electrocardiographic  ﬁndings.  Among  acute
I  patients,  ST-segment  elevation  myocardial  infarction
STEMI)  was  deﬁned  by  the  presence  of  new  ST-segment
levation  of  at  least  1  mm  (0.1  mv)  in  continuous  leads  or
ew  left  bundle-branch  block  on  the  index  of  electrocar-
iogram.  Recurrent  MI  was  deﬁned  as  recurrence  of  clinical
ymptoms  or  occurrence  of  electrocardiographic  changes
ccompanied  by  a  recurrent  increase  of  creatine  kinase-MB
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to  3  times  the  upper  limit  of  normal.  Stent  thrombosis  was
deﬁned  as  deﬁnite  and  probable  stent  thrombosis  accord-
ing  to  the  Academic  Research  Consortium  deﬁnition  [16].
Left  main  (LM)  complex  lesion  was  deﬁned  as  signiﬁcant
stenosis  of  LM  trunk  artery  with  the  presence  of  other  epicar-
dial  coronary  artery  stenosis.  The  morphology  of  lesions  in
coronary  angiography  was  classiﬁed  by  criteria  of  ACC/AHA
[17].  The  degree  of  coronary  ﬂow  was  classiﬁed  by  TIMI
grade  ﬂow  [18]. Renal  function  was  assessed  by  estimated
glomerular  ﬁltration  rate  (eGFR)  using  the  new  Japanese
equation  of  eGFR  [19]  was  used  to  calculate  eGFR  because
Korean  and  Japanese  have  a  lot  in  common  in  terms  of
race  or  physical  constitution  and  so  on.  GP  IIb/IIIa  inhibitors
during  PCI  was  administered  intravenously  or  through  intra-
coronary  at  a  dose  of  0.25  mg/kg.  LVEF  was  checked  by
2-dimensional  echocardiography.  Door-to-balloon  time  was
deﬁned  as  the  time  between  arrival  at  the  hospital  and  the
ﬁrst  balloon  inﬂation  or  device  deployment,  and  symptom-
to-balloon  time  was  deﬁned  as  the  time  between  onset  of
MI  and  the  ﬁrst  balloon  inﬂation  or  device  deployment.
Success  of  primary  PCI  was  deﬁned  as  residual  diame-
ter  stenosis  less  than  30%  and  a  ﬁnal  TIMI  3  grade  ﬂow.
Use  of  supportive  treatment  was  deﬁned  as  necessity  of
cardio-pulmonary  resuscitation,  intra-aortic  balloon  pump-
ing,  intubation,  deﬁbrillation/cardioversion,  and  temporary
pacemaker.
Clinical  follow  up  was  performed  at  12  months.  Major
adverse  cardiac  events  (MACE)  included  cardiac  death,  non-
fatal  MI,  repeat  revascularization.  Repeat  revascularization
included  target  lesion  revascularization  (TLR)  and  target
vessel  revascularization  (TVR).  TLR  was  deﬁned  as  a  repeat
intervention  in  the  stent  or  within  5  mm  proximal  or  distal
to  the  stent,  and  TVR  was  deﬁned  as  a  repeat  revasculariza-
tion  of  a  lesion  in  the  same  epicardial  vessel  treated  in  the
index  procedure  [20].
Statistical  analysis
All  analyses  were  performed  using  SPSS  software  version
17.0  (SPSS  Inc.  Chicago,  IL,  USA).  Continuous  variables
are  presented  as  mean  ±  standard  deviation  or  medians
and  interquartile  ranges,  and  compared  by  Student’s  t
tests,  Welch  t  tests,  or  Mann—Whitney  nonparametric  tests.
Categorical  variables  are  expressed  as  percentages  and  com-
pared  by  means  of  chi-square  test  or  Fisher’s  exact  test.  All
statistical  tests  were  2-tailed,  with  statistically  signiﬁcance
deﬁned  as  a  p-value  <0.05.  The  crude  survival  curves  were
made  using  the  Kaplan—Meier  method,  and  log-rank  tests
were  applied  to  evaluate  differences  between  the  treatment
groups.  A  propensity  score  was  created  to  adjust  confound-
ing  factors  using  a  logistic  regression  model.  Pretreatment
variables  which  occurred  before  TA  included:  age,  gender,
body  mass  index,  symptom  to  balloon  time,  door  to  bal-
loon  time,  resuscitation  prior  to  admission,  cardiopulmonary
arrest  on  arrival,  symptom  aspects,  presence  of  chest  symp-
tom,  presence  of  dyspnea,  presence  of  previous  angina
symptoms  before  MI  onset,  systolic  blood  pressure,  heart
rate,  Killip  class  on  presentation,  previous  ischemic  heart
disease,  history  of  hypertension,  diabetes  mellitus,  hyper-
lipidemia,  smoker,  family  history  of  heart  disease,  eGFR,
location  of  culprit  coronary  lesion,  LM  complex  disease,
(

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ultivessel  disease,  thrombolysis  before  PCI,  preprocedu-
al  TIMI  ﬂow  grade,  use  of  GP  IIb/IIIa  inhibitors  during  PCI,
nd  use  of  intravascular  ultrasound  (IVUS)  examination.  The
redicted  accuracy  of  the  logistic  model  was  assessed  by
he  area  under  the  receiver  operating  characteristic  curve
c  statistic),  which  was  0.718.  Adjusted  survival  curves
ere  calculated  with  the  use  of  the  Cox  regression  models
djusted  by  propensity  score  and  important  risk  covariates
hich  showed  p  <  0.2  in  univariate  analysis  for  end-points
nd  other  variables  that  have  been  reported  to  be  associated
ith  prognosis  of  patients  with  acute  MI.  Included  covari-
tes  are  age,  gender,  types  of  stent,  LVEF,  eGFR,  use  of  GP
Ib/IIIa  inhibitors  in  hospital,  medications  at  discharge  [e.g.
-blocker,  angiotensin-converting  enzyme  inhibitor  (ACE-I)
r  angiotensin  II  receptor  blocker  (ARB),  nitrate,  nicorandil,
pironolactone,  and  statin].  The  results  are  presented  as
djusted  hazard  ratios  (HRs)  with  95%  conﬁdence  intervals
CIs).  Although  subgroup  analyses  were  also  analyzed  using
he  Cox  regression  models  adjusted  by  propensity  score,
nly  MACE  could  be  analyzed  due  to  a  diminished  number
f  patients.
esults
aseline  clinical  and  procedural  characteristics
aseline  clinical  characteristics  and  medication  are  given
n  Table  1.  Patients  in  the  non-TA  group  were  older,  had
 higher  prevalence  of  previous  angina  symptoms  before
I  onset,  and  received  thrombolysis  therapy  prior  to  PCI.
atients  in  the  TA  group  had  a  higher  prevalence  of  family
istory,  cardiopulmonary  arrest  on  arrival,  low  blood  pres-
ure  on  admission,  high  Killip  class,  low  LVEF,  and  low  eGFR.
he  use  of  nitrate  and  nicorandil  was  higher  in  the  non-TA
roup.  Patients  in  the  TA  group  were  more  often  men  and
he  use  of  spironolactone  was  higher  in  this  group.
The  prevalence  of  LAD  as  culprit  lesion  and  type  B2/C
ere  higher  in  non-TA  group  whereas  RCA  was  higher  in  TA
roup.  Periprocedural  TIMI  ﬂow  grade  of  the  TA  group  was
ower  than  that  of  the  non-TA  group.  Time  to  procedure  was
horter  in  the  TA  group  than  in  the  non-TA  group.  The  fre-
uency  of  IVUS  usage  was  higher  in  the  non-TA  group  and
rug-eluting  stent  implantation  was  higher  in  the  TA  group
Table  2).
welve-month  clinical  outcomes
linical  outcomes  at  12  months  are  shown  in  Table  3.  While
here  were  no  signiﬁcant  differences  in  the  incidence  of
ACE,  cardiac  death,  repeat  revascularization,  and  stent
hrombosis,  the  rate  of  non-fatal  MI  was  signiﬁcantly  lower
n  the  TA  group  than  in  the  non-TA  group  (0.7%  vs  2.2%,
 =  0.010).
According  to  the  multivariate  analysis,  LVEF  <  35%  was
dentiﬁed  as  an  independent  predictor  of  12-month  MACE
adjusted  HR:  2.152,  95%  CI  1.124—4.121).  Prescription  of
-blockers  was  associated  with  a  decreased  non-fatal  MI
adjusted  HR:  0.182,  95%  CI  0.055—0.607).  Adjusted  sur-
ival  curves  are  shown  in  Fig.  1.  There  were  no  signiﬁcant
252  D.  Hachinohe  et  al.
Table  1  Baseline  clinical  characteristics  and  medication.
TA  (−)  TA  (+)  p-Value
(n =  1360)  (n  =  745)
Clinical
Age  (years)  62.6  ±  12.9  61.0  ±  12.9  0.005
Male gender,  n  (%)  998  (73.4%)  585  (78.7%)  0.007
Body mass  index  (kg/m2)  24.0  ±  3.2  24.2  ±  3.1  0.138
Risk factors
Hypertension,  n  (%) 609 (45.6%)  344  (47.1%)  0.549
Diabetes mellitus,  n  (%) 329 (24.7%)  172 (23.5%)  0.555
Hyperlipidemia,  n  (%) 155 (12.3%)  93 (13.2%)  0.571
Coronary artery  disease,  n  (%) 148 (11.0%)  72 (9.8%)  0.413
Smoker, n  (%)  828  (61.9%)  476  (65.5%)  0.115
Family history  of  heart  disease,  n  (%)  102  (8.2%)  96  (14.0%)  <0.001
Previous angina  symptoms  before  onset,  n  (%)  549  (40.8%)  220  (29.9%)  <0.001
Resuscitation  prior  to  arrival,  n  (%)  25  (1.8%)  12  (1.6%)  0.863
Cardiopulmonary  arrest  on  arrival,  n  (%)  0  (0%)  4  (0.5%)  0.016
Systolic blood  pressure  <100,  n  (%)  143  (10.8%)  99  (13.9%)  0.044
Heart rate  >  100,  n  (%)  108  (8.2%)  67  (9.4%)  0.362
Killip class  >  1,  n  (%)  318  (24.3%)  268  (38.6%)  <0.001
Thrombolysis  prior  to  PCI,  n  (%)  111  (8.2%)  39  (5.2%)  0.013
Left ventricular  ejection  fraction  52.4  ±  13.6  50.9  ±  19.8  0.043
Left ventricular  ejection  fraction  <  35%,  n  (%)  91  (7.2%)  42  (6.3%)  0.509
eGFR (mL/min/1.73  m2)  61.6  ±  30.5  58.8  ±  20.4  0.028
eGFR <  60,  n  (%) 708  (52.3%)  402  (54.5%)  0.336
Medication  in  hospital
Platelet  GPIIb/III  a  inhibitor,  n  (%) 322  (24.4%)  199  (27.1%)  0.186
Low molecular  weight  heparin,  n  (%)  241  (19.7%)  122  (21.0%)  0.530
Medication  at  discharge
Aspirin,  n  (%) 1296 (98.9%)  717  (98.5%)  0.538
Clopidogrel,  n  (%) 1301 (98.9%)  714(98.5%)  0.537
Cilostazol, n  (%) 346 (27.3%)  177  (24.7%)  0.203
Ca channel  blocker,  n  (%) 82 (6.5%)  42 (5.9%)  0.630
Beta blocker,  n  (%) 1102 (84.7%)  616 (85.6%)  0.649
ACE-I or  ARB,  n  (%) 1148 (87.5%)  638 (87.8%)  0.889
Nitrate, n  (%) 657 (51.4%)  297 (41.4%)  <0.001
Nicorandil, n  (%)  280  (22.2%)  110  (15.4%)  <0.001
Diuretics, n  (%)  221  (17.5%)  140  (19.6%)  0.249
Spironolactone,  n  (%)  106  (8.4%)  84  (11.8%)  0.017
Statin, n  (%)  984  (75.6%)  559  (77.3%)  0.384
Fibrate, n  (%)  5  (0.4%)  6  (0.8%)  0.221
Values are expressed as number (%) or mean (±SD). TA, thrombus aspiration; PCI, percutaneous coronary intervention; eGFR, estimated
glomerular ﬁltration rate; GP, glycoprotein; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.
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ubgroup  analysis
ig.  2  represents  subgroups’  HR,  95%  CI  and  p-value  of  TA
or  MACE  in  comparison  with  the  non-TA  group.  Administra-
ion  of  GP  IIb/IIIa  inhibitors  during  primary  PCI  (adjusted
R  0.329,  95%  CI  0.126—0.860,  p  =  0.023)  and  LAD  as  culprit
esion  (adjusted  HR  0.516,  95%  CI  0.275—0.971,  p  =  0.040)
ere  the  settings  in  which  TA  was  associated  with  a  lower
ACE  rate  compared  to  non-TA.
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his  study  was  designed  to  examine  whether  TA  during  pri-
ary  PCI  adds  beneﬁt  in  reducing  clinical  events  for  patients
ith  acute  STEMI.  Furthermore,  we  investigated  in  which
ettings  TA  was  effective  to  reduce  clinical  events.  Although
nadjusted  analysis  showed  TA  to  be  associated  with  a
ecreased  non-fatal  MI,  Cox  regression  models  adjusted
y  propensity  score  revealed  no  signiﬁcant  differences
etween  the  two  groups.  In  subgroup  analyses,  GP  IIb/IIIa
nhibitor  administration  combined  with  TA  gave  a  synergis-
ic  effect  and  TA  for  LAD  as  culprit  lesion  was  effective  in
erms  of  reducing  MACE.
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Table  2  Coronary  angiographic  and  procedural  characteristics.
TA  (−)  TA  (+)  p-Value
(n =  1360)  (n  =  745)
Angiographic
Left  main  complex,  n  (%)  37  (2.7%)  12  (1.6%)  0.130
Multivessel,  n  (%)  676  (50.1%)  355  (48.2%)  0.436
Infarct-related  artery
Left  main  trunk,  n  (%) 17 (1.3%)  9 (1.2%)  1.000
Left anterior  descending,  n  (%) 733 (54.4%)  340 (46.1%)  <0.001
Left circumﬂex,  n  (%) 155 (11.5%)  75 (10.2%)  0.381
Right coronary  artery,  n  (%) 442 (32.8%)  313 (42.5%)  <  0.001
Type B2/C  lesion,  n  (%)  945  (79.0%)  470  (70.0%)  <0.001
Preprocedural  TIMI  ﬂow  grade  0,  n  (%)  692  (54.7%)  450  (63.3%)  <0.001
Postprocedural  TIMI  ﬂow  grade  3,  n  (%) 1197  (94.3%)  629  (90.5%)  0.002
Procedural
Symptom to  balloon  time,  median  (IQR),  hours  5.7  (3.2—12.6)  4.7  (2.7—12.08)  0.100
Symptom to  balloon  time  <  4  h,  n  (%)  509  (39.4%)  311  (45.3%)  0.013
Door to  balloon  time,  median  (IQR),  minutes  71.0  (45.0—172.8)  55.0  (35.0—95.0)  <0.001
Door to  balloon  time  <  90  min,  n  (%)  814  (62.1%)  480  (69.4%)  0.001
Use of  IVUS,  n  (%)  263  (57.7%)  193  (27.0%)  <0.001
Administration  of  GP  IIb/IIIa  inhibitor,  n  (%)  402  (29.7%)  237  (32.2%)  0.253
Drug-eluting  stent  implantation,  n  (%)  1073  (85.0%)  605  (88.7%)  0.027
Stent length    25  mm,  n  (%) 474  (37.3%)  260  (38.1%)  0.732
Stent diameter    2.5  mm,  n  (%)  89  (7.0%)  42  (6.1%)  0.508
Success of  primary  PCI,  n  (%) 1293  (96.9%)  697  (97.2%)  0.688
Intraprocedural  complications,  n  (%) 225 (16.6%)  110  (14.9%)  0.319
Supportive treatment,  n  (%) 192  (14.2%)  109  (14.9%)  0.696
Values are expressed as number (%) or median (IQR, interquartile range); TA, thrombus aspiration; Type B2/C, according to lesion mor-
phology of American College of Cardiology/American Heart Association; TIMI, Thrombolysis In Myocardial Infarction; IVUS, intravascular
ion. S
pora
l
t
u
o
a
T
s
c
pultrasound; GP, glycoprotein; PCI, percutaneous coronary intervent
balloon pumping, intubation, deﬁbrillation/cardioversion, and tem
Primary  PCI  and  stenting  are  considered  the  gold  standard
strategy  in  patients  with  STEMI  [1,2]. Apparent  decreased
ﬂow  in  the  infarct-related  artery  and  suboptimal  myocar-
dial  reperfusion  make  prognosis  worse  and  were  caused  by
multiple  factors  such  as  myocardial  dysfunction  accompa-
nied  by  vessel  endothelial  swelling  and  myocardial  edema
due  to  myocardial  ischemia,  and  embolization  of  plaque,
thrombotic,  or  inﬂammatory  materials  [21]. TA  may  be
effective  to  avoid  embolization  of  plaque  or  thrombotic
debris  [22]. Although  recent  RCTs  [3—5]  and  two  different
meta-analyses  [6,7]  demonstrated  that  TA  improved  reper-
fusion  surrogate  and  clinical  end  points  and  2009  ACC/AHA
guidelines  for  STEMI  [8]  raised  advisability  of  TA  to  Class  II  a,
f
u
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Table  3  Clinical  outcomes  at  12  months.
TA  (
(n =
Total  major  adverse  cardiac  events,  n  (%)  134
Cardiac death,  n  (%)  31
Non-fatal myocardial  infarction,  n  (%)  29
Repeat revascularization,  n  (%)  60
Stent thrombosis  (deﬁnite/probable),  n  (%)  25
Values are expressed as number (%). TA, thrombus aspiration. Majo
infarction, repeat revascularization. Repeat revascularization: target lupportive treatment: cardiopulmonary resuscitation, intra-aortic
ry pacemaker.
evel  of  Evidence  B,  in  this  study,  we  failed  to  demonstrate
hat  TA  improved  clinical  outcomes  in  STEMI  patients  who
nderwent  primary  PCI.  In  our  study,  since  the  incidence
f  12-month  MACE  was  relatively  low  (non-TA  group:  10.0%
nd  TA  group:  7.5%)  compared  with  the  TAPAS  study  (non-
A  group:  20.3%  and  TA  group:  16.6%),  our  study  might  be
ubstantially  underpowered  to  demonstrate  differences  in
linical  outcomes.  In  addition,  retrospective  analyses  using
ropensity  score  and  Cox  regression  models  to  correct  con-
ounding  factors  may  affect  the  results.
On  another  front,  in  the  present  subgroup  analyses,  the
se  of  GP  IIb/IIIa  inhibitor  and  culprit  lesion  in  LAD  were
he  settings  in  which  MACE  were  improved.  Since  distal
−)  TA  (+)  p-Value
 1360)  (n  =  745)
 (10.0%)  56  (7.5%)  0.068
 (2.3%)  13  (1.7%)  0.430
 (2.2%)  5  (0.7%)  0.010
 (4.5%)  25  (3.4%)  0.248
 (2.1%)  19  (3.4%)  0.141
r adverse cardiac events: cardiac death, non-fatal myocardial
esion revascularization and target vessel revascularization.
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Figure  1  Adjusted  12-month  survival  curves.  Adjusted  survival  curves  stratiﬁed  according  to  treatment  groups.  (A)  The  composite
of major  adverse  cardiac  events  (cardiac  death,  non-fatal  myocardial  infarction,  target  lesion  revascularization  and  target  vessel
revascularization).  (B)  Cardiac  death.  (C)  Non-fatal  myocardial  infarction.  (D)  Target  lesion  revascularization  and  target  vessel
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tevascularization.  MACE,  major  adverse  cardiac  events;  TA,  t
yocardial infarction;  TLR,  target  lesion  revascularization;  TVR
mbolization  is  the  most  important  cause  of  impaired  epi-
ardial  ﬂow  and  suboptimal  myocardial  reperfusion,  which
ften  occur  after  ballooning  or  stenting,  physicians  might
redict  and  avoid  it.  In  fact,  the  presence  of  lipid  pool,
oating  thrombus,  and  attenuation  plaque  are  linked  to  no
eﬂow  phenomenon,  which  is  deﬁned  as  an  acute  reduc-
ion  in  coronary  ﬂow  (TIMI  grade  0—1)  without  dissection,
hrombus,  spasm,  or  high-grade  residual  stenosis  at  the  tar-
et  lesion  [23]. As  shown  in  Table  2,  IVUS  was  performed
ore  than  twice  in  patients  without  TA  than  those  with.  In
he  TA  group,  thrombi  might  be  cleared  out  and  show  good
ngiographical  results  compared  with  the  non-TA  group.  On
he  other  hand,  in  the  non-TA  group,  there  might  remain
ome  thrombi  or  plaque  burden  after  ballooning  or  stenting.
his  might  make  physicians  decide  to  use  IVUS  in  the  non-
A  group.  Although  mechanical  removal  of  thrombi  might
educe  the  existing  source  of  embolization,  platelet  aggre-
ates  cannot  be  abolished  completely.  With  respect  to  the
L
F
abus  aspiration;  HR,  hazard  ratio;  CI,  conﬁdence  interval;  MI,
get  vessel  revascularization.
se  of  GP  IIb/IIIa  inhibitors,  it  has  been  reported  that  it  pro-
ects  from  ill  effects  of  platelet  aggregation  and  improves
icrovascular  dysfunction  [24,25].  Therefore,  combined  use
f  mechanical  removal  of  thrombi  and  GP  IIb/IIIa  inhibitors
uring  primary  PCI  may  have  a  synergistic  effect.  Regarding
ffectiveness  of  TA  for  LAD  as  culprit  lesion,  though  RCA  is
sually  more  thrombogenic  and  therefore  at  higher  risk  for
istal  embolization,  one  paper  has  reported  that  TA  had  a
ositive  impact  on  proximal  LAD  in  addition  to  RCA  lesions
26].  If  we  can  avoid  no-reﬂow  phenomenon  in  LAD  which
upplies  the  largest  territory  of  epicardial  coronary  arteries,
here  is  a  possibility  to  improve  clinical  outcomes.imitations
irst,  this  study  was  based  on  observational  registry  data
nd  control  status  of  risk  factors  during  follow-up  was  not
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Figure  2  Hazard  ratios  (HR)  and  95%  conﬁdence  interval  (CI)  for  the  composite  major  adverse  cardiac  events  (cardiac  death,
myocardial infarction,  target  lesion  revascularization  and  target  vessel  revascularization)  according  to  baseline  clinical  and  proce-
dural subgroups.  GP,  glycoprotein;  LAD,  left  anterior  descending  artery;  LCX,  left  circumﬂex  artery;  RCA,  right  coronary  artery;  TIMI,
Thrombolysis In  Myocardial  Infarction;  IVUS,  intravascular  ultrasound;  LVEF,  left  ventricular  ejection  fraction;  PCI,  percutaneous
t
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available  and  only  medications  at  discharge  were  avail-
able  as  reference  index  of  risk  management.  We  used  Cox
regression  models  adjusted  by  propensity  score  to  correct
confounding  factors,  however,  the  result  may  be  inﬂuenced
by  the  nonrandomized  assignment  and  some  confounding
factors.  Randomized  evaluation  will  be  needed  for  more
accurate  evaluation.  However,  we  deem  this  study  worth-
while  owing  to  its  large  number  of  patients  and  appropriate
method  of  statistical  analysis.  Second,  in  spite  of  the  pres-
ence  of  TIMI  ﬂow  grade  in  this  registry,  there  was  no
information  about  other  markers  of  myocardial  perfusion
such  as  corrected  TIMI  frame  count,  myocardial  blush  grade,
and  ST-segment  resolution  that  were  linked  to  prognosis
more  precisely  [27—29]. In  addition,  although  collateral
ﬂow  would  affect  the  prognosis  after  primary  PCI,  the  data
regarding  collateral  ﬂow  to  culprit  vessels  were  not  avail-
able  in  this  registry.  Third,  thrombus  score  and  presence
or  absence  of  thrombus  were  not  recorded,  so  we  could
not  identify  what  made  physicians  decide  to  use  TA  device.
Forth,  adverse  events  about  TA  and  cumulative  data  of  stent
thrombosis  were  not  available.  Fifth,  we  could  not  evaluate
T
S
A
whe  percent  of  patients  in  whom  Reopro  was  administered
.c.  vs  i.v.  and  investigate  the  difference  between  the  two
roups.
onclusions
lthough  TA  did  not  improve  clinical  outcomes  in  overall
TEMI  patients  who  underwent  primary  PCI,  the  use  of  TA
or  LAD  occlusion  will  improve  12-month  MACE.  Further-
ore,  combined  use  of  GP  IIb/IIIa  inhibitors  with  TA  has  a
ynergistic  effect.
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